Promoting Diversity and Science

for Health Equity-- Introduction of NIDA

Minority Diversity Programs

Yu (Woody) Lin, M.D., Ph.DProgram Director

Division of Clinical Neuroscience and Behavior Research

National Institute on Drug Abuse/NIH

NIH Mission

NIH is the steward of medical and behavioral research for the Nation

Our mission: to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability … • Support research by non-Federal scientists across

U.S. and abroad• Help train research investigators• Foster communication of medical and health

sciences information

Training 2% $722 Million

Research Project Grants 53%

$16.42 Billion

Total NIH Budget Authority – FY 2011$32.23 Billion

NIDA’s Mission

- Support and conduct cross-disciplinary research to better understand, treat and prevent drug abuse and addiction

- Disseminate research results to improve prevention, treatment, and policy

Bring the power of science to bear research on drug abuse and addiction

NIDA Research NIDA Research

…To Genetics…To Genetics

From Molecules…

…Drug Courts…Drug Courts…Health Services Research…Health Services Research

… Behavioral Treatment… Behavioral Treatment

NIDA BUDGET(Thousands)

Increase Over

Prior Year

AIDS

TOTAL

NonAIDS

2011

$731,428

$317,348

$1,048,776

-1.0%

2012

$732,822

$319,292

$1,052,114

0.3%

2013PB

$732,838

$321,163

$1,054,001

0.2%

National Institute on Drug Abuse Portfolio FY 2010 Actual

Epidemiology, Services & Prevention Research -- 23%

Basic & Clinical Neuroscience & Behavioral Research -- 46%

Pharmacotherapies & Medical Consequences -- 12%

Intramural Research -- 8%

Clinical Trials Network -- 4%

RM&S -- 6%

National Institute on Drug Abuse

Office of Extramural Affairs

Teresa Levitin, PhD

Gender ResearchCora Lee Wetherington, PhD

HIV/AIDS ResearchJacques Normand, PhD

International ProgramSteve Gust, PhD

Office of Planning & Resource

Management

Helio Chaves

Office of Science Policy & Communications

Susan Weiss, PhD

Center for the Clinical Trials

Network

Betty Tai, PhD

Division of Basic Neuroscience &

Behavioral Research

Joni Rutter, PhD

Division of Pharmacotherapies &

Medical Consequences of Drug Abuse

David McCann, PhD

Division of Epidemiology, Services & Prevention Research

Wilson Compton, MD, MPE

Division of Clinical Neuroscience &

Behavioral Research

Joseph Frascella, PhD

Intramural Research Program

Anto Bonci, MD

Special Populations OfficeDavid Shurtleff, PhD

Office of the DirectorNora D. Volkow, MD

DirectorDavid Shurtleff, PhD

Acting Deputy DirectorGlenda Conroy

Executive Officer

Special Populations Office (SPO)

What We Do:

The NIDA Special Populations Office (SPO) aims are to:

(1) increase the number of underrepresented scholars and researchers actively participating in drug abuse research through our outreach, and sponsored career development and research training programs

(2) ensure that minority/health disparity issues and research are adequately and appropriately represented in NIDA’s extramural research programs as described in NIDA’s strategic plan in addressing health disparities.

National Institutes of Health • Increase diverse workforce & activity• Promote science for health equity

Special Populations Office (SPO)

SPO DIRECTOR

NIDA Diversity Research Program

SPO STAFF

NHSNWorkgrou

p

AA RS Workgrou

p

AAPI RS Workgrou

p

NA/AN RS

Workgroup

Special Populations Office (SPO)

The NIDA SPO coordinates the Institute’s diversity-directed research, concentrating on areas where there are significant gaps

in knowledge and/or clear Disparities in prevention and treatment.

Researchers & Scholars Workgroups

Each Work Group is currently comprised of established researchers and scholars with expertise in drug abuse and addiction research and health concerns of the particular population it represents.

1.Provide guidance and recommendations to NIDA:• Drug abuse and addiction research development• Training needs within 4 major diverse populations

2.Identify concerns, and stimulate research on drug abuse/addiction associated with particular population it represents.

American Indian/ Alaska

Native Work Group

African American

Work Group

SPO Research & Training Programs

Promoting Diversity and Science

for Health Equity

Diversity -promoting Institutions Drug Abuse Research Program (DIDARP)

Diversity Supplements

Research Development Seminar Series

Summer Research with NIDA

NIDA Diversity-Promoting Institutions Drug Abuse Research Program (DIDARP)

The overall goal of the DIDARP is the capacity development of the applicant institution to support drug abuse research through the following objectives:

http://grants.nih.gov/grants/guide/pa-files/PAR-11-060.html

(1) Provide faculty with drug abuse research knowledge and skill development through the conduct of research projects and other professional development activities; (2) Encourage students from disadvantaged backgrounds to pursue drug abuse research careers by providing them with educational enrichment and research experiences;

(3) Strengthen the underlying institutional infrastructure needed to support drug abuse research. (4) Budgets up to $350,000 (direct costs/year (5 years); NIDA review, division fund

Since 2005, NIDA has supported 15 DIDARPs. There are 11 active DIDARP projects; including these 7 institutions that have not been previously supported:

• University of Houston• Howard University• Meharry Medical College• Morehouse School of Medicine• University of Puerto Rico School of Public Health• California State University – San Bernandino • University of Hawaii

• NIDA Program Contact: Pamela Goodlow

NIDA Diversity-Promoting Institutions Drug Abuse Research Program (DIDARP)

15

•Supplements certain active (> 1 year) research grants • Provides mentoring/training for an identified individual

from an underrepresented or disadvantaged population:

* Racial/Ethnic Minority * Investigator who becomes disabled* Individual with disability * Disadvantaged Background

• Supports persons at five levels:

* High school * Undergraduates* Graduate students * Post doctoral* Investigators

• NIDA internal review; a NIH-wide program• Type/Amount of support varies with levels

NIDA Program Contact: Pamela Goodlow

Diversity Supplements Program

16

NIDA Diversity Supplement Awards

FY New Awards Continuing Awards

Total Awards

FY 1994 21 21 42FY 1995 35 18 53FY 1996 41 26 67FY 1997 34 28 62FY 1998 35 32 67FY 1999 41 20 61FY 2000 30 41 71FY 2001 38 23 61FY 2002 31 23 54FY 2003 32 26 58FY 2004 40 24 64FY 2005 38 28 66FY 2006 38 38 76FY 2007 35 36 71FY 2008 29 26 55FY 2009 32 19 51Total 550 979

Research Development Seminar Series

• For scholars from diverse populations who are trained & dedicated for independent research on drug abuse yet need technical assistance on grant application process

• Small group discussion, and one-on-one mentoring provided by NIDA staff and extramural experts in the field of drug abuse and addiction research

• NIDA Program Contact: Flair Lindsey

• Provides science and proposal development lectures in 2 training sessions about 6 months apart:• First focuses on research design, methods, scientific writing,

the peer review process and grant application preparation• Second centers on mock review led by NIDA SRA

• Must prepare a 1-page concept paper • Actively participate in proposal development activities• Expectation is that your application will be submitted

within 6 – 12 months after your last session

Research Development Seminar Series

Program established in 1986. From 2009 – 2011 NIDA supported 57 early career researchers to attend the Seminar Series

Examples of NIDA-Supported Research In Diverse Communities

• Patterns of Substance Abuse

• Biological & Behavioral Risk & Protective Factors

• Relationship of Stress to Drug Use & Other Disorders

• Culturally Appropriate Prevention Interventions

• Preventive Interventions with Urban Youth

• Culturally Appropriate Substance Abuse Treatment Strategies

• Tobacco Cessation

• Treatment Services Research

NIDA Summer Research Internship Program

• Supports under-represented high school and undergraduate students in the social sciences and life sciences

• 8-10 week research placement with NIDA grantees

Gender Ethnicity

FY F M AA Hispanic AI/AN AAPI TOTAL

FY 1997 16 6 16 5 1 -- 22

FY 1998 15 7 17 3 1 1 22FY 1999 31 8 31 4 3 1 39FY 2000 25 7 19 6 3 4 32FY 2001 25 15 25 3 3 9 40FY 2002 54 22 46 12 8 10 76FY 2003 48 24 43 11 5 13 72FY 2004 52 18 56 6 2 6 70FY 2005 58 26 50 21 3 10 84FY 2006 63 14 49 17 2 9 77FY 2007 37 15 29 14 -- 9 52FY 2008 36 18 28 13 3 10 54FY 2009 45 17 33 5 -- 24 62FY 2010 50 23 34 16 3 14 73FY 2011 55 15 28 16 1 11 70TOTAL 610 235 504 152 38 131 845

Summer Research with NIDAProgram Participation - All Years

22

NIDA Minority Diversity Programs

• Preparing researchers to better address minority health disparities

• Stimulating/Encouraging research that will lead to more effective drug abuse and drug abuse related prevention and treatment approaches for racial/ethnic minority populations

• Increasing the number of racial/ethnic minority researchers engaged in drug abuse and related research

National Institute on Drug Abuse

NIDA Has Made a Commitment in You

• Believe in your research skills and abilities

• Your research has the potential to make an impact in the substance abuse and health disparities field

Questions?

Funding Opportunity Announcements:NIMHD Basic and Applied Biomedical Research on Minority Health and Health Disparities (R01) RFA-MD-12-004

NIMHD Social, Behavioral, Health Services, and Policy Research on Minority Health and Health Disparities (R01)RFA-MD-12-003

Conferences and Scientific Meetings PA-10-071

National Institute on Minority Health and Health Disparities

In 2010, NIH announced the transition of the National Center on Minority Health and Health Disparities (NCMHD) into the National Institute on Minority Health and Health Disparities (NIMHD).

This transition gives the institute a more defined role in the NIH's research agenda against health disparities, which it defines as differences in the incidence, prevalence, mortality, and burden of diseases and other adverse health conditions that exist among specific population groups.